Patents Assigned to President and Fellows of Harvard College
-
Patent number: 11809061Abstract: Kerr and electro-optic frequency comb generation in integrated lithium niobate devices is provided. In various embodiments, a microring resonator comprising lithium niobate is disposed on a thermal oxide substrate. The microring resonator has inner and outer edges. Electrodes are positioned along the inner and outer edges of the microring resonator. The electrodes are adapted to modulate the refractive index of the microring. A pump laser is optically coupled to the microring resonator. The microring resonator is adapted to emit an electro-optical frequency comb when receiving a pump mode from the pump laser and when the electrodes are driven at a frequency equal to a free-spectral-range of the microring resonator.Type: GrantFiled: October 20, 2022Date of Patent: November 7, 2023Assignees: President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mian Zhang, Cheng Wang, Marko Loncar, Brandon Taylor Buscaino, Joseph M. Kahn
-
Patent number: 11807895Abstract: A method for detecting oncogenic growth and viability, and/or degree of cellular transformation and/or identifying an agent that inhibits cellular transformation is disclosed. The method including: providing a cellular sample, such as a sample of cells obtained from a subject or a cell line; culturing the cellular sample in low attachment conditions; and detecting growth and7or cell viability of the sample, wherein increased growth relative and/or viability relative to a control or control level indicative of basal growth and/or viability indicates cellular transformation. In some embodiments, the method includes introducing a n expression vector into cells of the cellular sample, wherein the expression vector comprises a gene product expression sequence being tested for transformation ability. In some embodiments the cellular sample is contacted with a test agent and growth and/or cell viability of the sample is determined to determine if the agent inhibits transformation.Type: GrantFiled: March 24, 2016Date of Patent: November 7, 2023Assignees: THE BROAD INSTITUTE, INC., DANA FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Asaf Rotem, Kevin Struhl, Paul Blainey, Liyi Xu
-
Patent number: 11807677Abstract: Described herein are engineered microbe-targeting molecules, microbe-targeting articles, kits comprising the same, and uses thereof. Such microbe-targeting molecules, microbe-targeting articles, or the kits comprising the same can not only bind or capture of a microbe or microbial matter thereof, but they also have improved capability (e g, enhanced sensitivity or signal intensity) of detecting a microbe or microbial matter. Thus, the microbe-targeting molecules, microbe-targeting articles, and/or the kit described herein can be used in various applications, e.g., but not limited to assays for detection of a microbe or microbial matter, diagnostic and/or therapeutic agents for diagnosis and/or treatment of an infection caused by microbes in a subject or any environmental surface, and/or devices for removal of a microbe or microbial matter from a fluid.Type: GrantFiled: December 16, 2021Date of Patent: November 7, 2023Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Alexander Watters, Brendon Dusel, Michael Super, Mark Cartwright, Donald E. Ingber
-
Patent number: 11806372Abstract: This application provides for methods of treatment for IBD, especially in subjects who have R. gnavus species or R. gnavus group IBD strains as a component of their microbiome. The application also provides for methods of diagnosing IBD, as well as kits for use in the claimed methods.Type: GrantFiled: April 20, 2018Date of Patent: November 7, 2023Assignees: The Broad Institute, Inc., The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: Andrew Brantley Hall, Ramnik Xavier, Curtis Huttenhower, Moran Yassour, Hera Vlamakis
-
Patent number: 11807871Abstract: A microfluidic device is directed to sustaining a complex microbial community in direct and indirect contact with living human intestinal cells in vitro. The device includes a first microchannel having cultured cells of a human intestinal epithelium and microbiota, the first microchannel further having a first level of oxygen. The device further includes a second microchannel having cultured cells of a vascular endothelium, the second microchannel further having a second level of oxygen. The device also includes a membrane located at an interface region between the first microchannel and the second microchannel, the membrane being composed of an oxygen-permeable material or further having pores via which oxygen flows between the first microchannel and the second microchannel to form a physiologically-relevant oxygen gradient.Type: GrantFiled: April 2, 2019Date of Patent: November 7, 2023Assignee: President and Fellows of Harvard CollegeInventors: Richard Novak, Sasan Jalili-Firoozinezhad, Francesca S. Gazzaniga, Elizabeth L. Calamari, Diogo M. Camacho, Bret A. Nestor, Cicely Fadel, Michael L. Cronce, Dennis L. Kasper, Donald E. Ingber, Amir Bein
-
Patent number: 11806441Abstract: Provided are fast relaxing hydrogels that are useful for regulating cell behavior and enhancing tissue regeneration, e.g., bone regeneration.Type: GrantFiled: June 15, 2021Date of Patent: November 7, 2023Assignee: President and Fellows of Harvard CollegeInventors: Luo Gu, Ovijit Chaudhuri, Nathaniel D. Huebsch, David J. Mooney, Max Carlton Darnell, Simon Young
-
Publication number: 20230348883Abstract: Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of nucleic acid programmable DNA binding proteins (napDNAbp), e.g., Cpf1 or variants thereof, and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a napDNAbp (e.g., CasX, CasY, Cpf1, C2c1, C2c2, C2C3, and Argonaute) and nucleic acid editing proteins or domains, are provided.Type: ApplicationFiled: December 15, 2022Publication date: November 2, 2023Applicant: President and Fellows of Harvard CollegeInventors: David R. Liu, Alexis Christine Komor, Liwei Chen, Holly A. Rees
-
Publication number: 20230348895Abstract: The technology described herein is directed to compositions and methods for determining provenance of an item, a non-limiting example being a food item. In one aspect described herein is an engineered microorganism comprising at least one genetic barcode element, essential gene mutations, and/or germination gene mutations. In another aspect described herein is a method of determining the provenance of an item comprising contacting the item with an engineered microorganism and later detecting the genetic barcode element to determine the provenance of the item. In another aspect, described herein is a method of determining the path of an item or individual across a surface.Type: ApplicationFiled: January 8, 2021Publication date: November 2, 2023Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Michael SPRINGER, David Z. RUDNER
-
Publication number: 20230349883Abstract: Systems and methods are provided for characterizing shuttle capture events in a nanopore sensor. The method first collects time-dependent current blockage signatures for at least one bias voltage. The method then identifies each signature as corresponding to a permanent or transient event. The method then generates a protein dynamics landscape (PDL) for the transient event signatures. The PDL comprises a set of histograms of nanopore current data and characterizes current through the nanopore during shuttle capture events. The method can then comprise identifying an entrance level blockage value based on the permanent event signatures. Permanent event captures can be determined by time duration which is larger than a certain threshold time value. Applying a voltage between the fluidic chambers above a threshold voltage level can be used to control that the vast majority of events are permanent.Type: ApplicationFiled: March 17, 2023Publication date: November 2, 2023Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Lene V. HAU, Jene A. GOLOVCHENKO
-
Publication number: 20230348958Abstract: The present invention generally relates to genomics. Some embodiments are directed to imaging the 3D organization of the genome, or part of the genome, with high throughput in the sequence space. Some embodiments are directed to imaging the 3D organization of the genome, or part of the genome, in the context of transcriptional activity and nuclear structures. In addition, certain embodiments are directed to chromatin structures, 3D chromatin organizations, trans-chromosomal interactions and chromatin-nuclear-structure interactions as well as their relationship with transcription, etc. In addition, various embodiments are directed to imaging methods that allow mapping of the 3D organization of the genome, or part of the genome, in the context of nuclear structures and transcriptional activity. Some embodiments are directed to massively multiplexed fluorescence in situ hybridization methods for imaging chromatin loci and/or nascent RNA transcripts at the chromosome or genome scale.Type: ApplicationFiled: December 18, 2020Publication date: November 2, 2023Applicant: President and Fellows of Harvard CollegeInventors: Xiaowei Zhuang, Bogdan Bintu, Seon S. Kinrot, Pu Zheng, Jun-Han Su
-
Publication number: 20230340467Abstract: Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and/or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named an PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incorporated into the target DNA molecule.Type: ApplicationFiled: May 31, 2023Publication date: October 26, 2023Applicants: The Broad Institute, Inc., President and Fellows of Harvard CollegeInventors: David R. Liu, Andrew Vito Anzalone, James William Nelson
-
Publication number: 20230340404Abstract: Embodiments herein described provide antigen-presenting cell-mimetic scaffolds (APC-MS) and use of such scaffolds to manipulating T-cells. More specifically, the scaffolds are useful for promoting growth, division, differentiation, expansion, proliferation, activity, viability, exhaustion, anergy, quiescence, apoptosis, or death of T-cells in various settings, e.g., in vitro, ex vivo, or in vivo. Embodiments described herein further relate to pharmaceutical compositions, kits, and packages containing such scaffolds. Additional embodiments relate to methods for making the scaffolds, compositions, and kits/packages. Also described herein are methods for using the scaffolds, compositions, and/or kits in the diagnosis or therapy of diseases such as cancers, immunodeficiency disorders, and/or autoimmune disorders.Type: ApplicationFiled: November 30, 2022Publication date: October 26, 2023Applicant: President and Fellows of Harvard CollegeInventors: Alexander Sing Cheung, David J. Mooney
-
Publication number: 20230340457Abstract: The technology described herein is directed to compositions, sets, and methods for analyzing, detecting, and/or visualizing target molecules. In one aspect, described herein are sets of readout molecules to determine the identity of at least one oligonucleotide tag hybridized to at least one target molecule. In another aspect, described herein are methods of detecting said oligonucleotide tags bound to at least one target molecules using said set of readout molecules.Type: ApplicationFiled: November 24, 2020Publication date: October 26, 2023Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Huy Quoc NGUYEN, Shyamtanu CHATTORAJ, Chao-ting WU
-
Publication number: 20230340466Abstract: Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and/or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named an PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incoporated into the target DNA molecule.Type: ApplicationFiled: May 31, 2023Publication date: October 26, 2023Applicants: The Broad Institute, Inc., President and Fellows of Harvard CollegeInventors: David R. Liu, Andrew Vito Anzalone, James William Nelson
-
Publication number: 20230338468Abstract: Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g.Type: ApplicationFiled: May 16, 2023Publication date: October 26, 2023Applicant: President and Fellows of Harvard CollegeInventors: David A. Sinclair, Yuancheng LU
-
Publication number: 20230341394Abstract: The present invention relates to a homogeneous, time resolved, Förster resonance energy transfer (TR-FRET)-based method for detection of SARS-CoV-2, SARS CoV-1, and MERS-CoV antibodies in a patient fluid sample.Type: ApplicationFiled: August 16, 2021Publication date: October 26, 2023Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Eric Fischer, Radoslaw Nowak, Hong Yue, Daan Overwijn, Ralph Mazitschek, Neil Connor Payne
-
Publication number: 20230340465Abstract: Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and/or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named an PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incorporated into the target DNA molecule.Type: ApplicationFiled: May 31, 2023Publication date: October 26, 2023Applicants: The Broad Institute, Inc., President and Fellows of Harvard CollegeInventors: David R. Liu, Andrew Vito Anzalone, James William Nelson
-
Publication number: 20230340038Abstract: The present disclosure, at least in part, relates to compositions (e.g., isolated nucleic acid and rAAVs) and methods for treating Non-syndromic hearing loss and deafness (DFNB1) by delivering gap junction beta 2 (GJB2) protein to inner ear cells that normally express GJB2 (e.g., fibrocytes and supporting cells of the organ of Corti and nearby regions). The isolated nucleic acid of the present disclosure comprises an expression cassette, wherein the expression cassette comprises a gap junction beta 2 (GJB2) gene regulatory element (GRE) (e.g., GJB2 enhancers, GJB2 promoters, GJB2 5? UTR, and/or GJB2 3? UTR), and a nucleotide sequence encoding a GJB2 protein.Type: ApplicationFiled: September 14, 2021Publication date: October 26, 2023Applicant: President and Fellows of Harvard CollegeInventors: David P. Corey, Kevin T. Booth, Cole W. D. Peters, Maryna V. Ivanchenko, Michael E Greenberg, Sinisa Hrvatin, Mark Aurel Nagy, Eric C. Griffith
-
Patent number: 11795452Abstract: Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and/or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named a PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incorporated into the target DNA molecule.Type: GrantFiled: May 23, 2022Date of Patent: October 24, 2023Assignees: The Broad Institute, Inc., President and Fellows of Harvard CollegeInventors: David R. Liu, Andrew Vito Anzalone
-
Patent number: 11795443Abstract: The disclosure provides methods and compositions for treating blood diseases/disorders, such as sickle cell disease, hemochromatosis, hemophilia, and beta-thalassemia. For example the disclosure provides therapeutic guide RNAs that target the promotor of HBG1/2 to generate point mutations that increase expression of fetal hemoglobin. As another example, the disclosure provides therapeutic guide RNAs that target mutations in HBB, Factor VIII, and HFE to treat sickle cell disease, beta-thalassemia, hemophilia and hemochromatosis. The disclosure also provides fusion proteins comprising a Cas9 (e.g., a Cas9 nickase) domain and adenosine deaminases that deaminate adenosine in DNA. In some embodiments, the fusion proteins are in complex with nucleic acids, such as guide RNAs (gRNAs), which target the fusion proteins to a DNA sequence (e.g., an HBG1 or HBG2 protmoter sequence, or an HFE, GBB, or F8 gene sequence).Type: GrantFiled: October 16, 2018Date of Patent: October 24, 2023Assignees: The Broad Institute, Inc., President and Fellows of Harvard College, Beam Therapeutics, Inc.Inventors: David R. Liu, Nicole Marie Gaudelli, Michael S. Packer, Gregory Newby